It will be quite a while yet before France's Erytech Pharma SA gets a product on the market after pulling its European submission for Graspa (eryaspase) for acute lymphoblastic leukemia (ALL) and deciding that solid tumors, particularly pancreatic cancer, represent the best way forward for the compound.
The Lyon-headquartered group said in a statement that "despite having observed favorable efficacy results and safety profile in multiple clinical...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

